V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330003731 | 330001885 | 1.65 | 89.25 | Adjuvant (A) | null | 2014-01-14 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330013781 | CISPLATIN + GEMCITABINE |
| 330003732 | 330001885 | 1.65 | 75.9 | Neo-adjuvant (N) | 2013-03-24 | 2013-03-30 | Dox + HD Mtx (post PAM) | N | N | 330013781 | DOXORUBICIN + HD MTX |
| 330003733 | 330001886 | 1.79 | null | Curative (C) | 2013-06-30 | 2013-07-08 | DA 3 + 10 | N | N | 330013810 | DA |
| 330003734 | 330007019 | 1.69 | 153.2 | null | 2015-04-11 | 2015-04-23 | CVP R | N | N | 330013821 | CVP R |
| 330003735 | 330007019 | 1.58 | 58 | Neo-adjuvant (N) | 2017-06-30 | 2017-06-30 | Dox + HD Mtx (post PAM) | Y | N | 330013821 | DOXORUBICIN + HD MTX |
| 330003736 | 330007019 | 1.58 | 31.4 | Curative (C) | 2016-01-14 | 2016-01-20 | DA 3 + 10 | N | N | 330013821 | DA |
| 330003737 | 330001887 | 1.61 | 48 | Disease modification (D) | null | 2017-01-17 | CVP R | null | null | 330013831 | CVP R |
| 330003738 | 330007020 | 1.65 | 69 | Curative (C) | 2015-01-30 | 2015-02-07 | DA | N | N | 330013832 | DA |
| 330003739 | 330007020 | 1.63 | 60 | Curative (C) | 2015-07-24 | 2015-08-01 | Cetuximab + Radiotherapy Load | N | Y | 330013832 | CETUXIMAB + RT |
| 330003740 | 330007020 | 1.54 | 79.5 | Disease modification (D) | 2013-11-19 | 2013-11-21 | Cyclophosphamide + Dex + Rituximab | 02 | N | 330013832 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003741 | 330001888 | 1.82 | 98.6 | Curative (C) | 2017-06-24 | 2017-07-01 | CYCLOPHOSPHAMIDE + RITUXIMAB | 2 | N | 330013860 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003744 | 330001890 | 1.52 | 61.7 | Curative (C) | 2014-04-03 | 2014-04-03 | DA | 02 | N | 330013869 | DA |
| 330003745 | 330001890 | 0 | 63.2 | Curative (C) | 2016-01-24 | 2016-01-28 | OST Euramos 1 Closed Trial - AP | 02 | N | 330013869 | MAP |
| 330003746 | 330001890 | 1.75 | 80 | Palliative (P) | 2017-06-24 | 2017-06-28 | OST Euramos 1 Closed Trial - AP | 02 | N | 330013869 | MAP |
| 330003747 | 330001890 | 1.84 | 88.05 | Curative (C) | 2015-04-01 | 2015-04-02 | Cetuximab + Radiotherapy Load | 02 | null | 330013869 | CETUXIMAB + RT |
| 330003748 | 330001891 | 1.78 | 57.2 | Curative (C) | 2016-06-17 | 2016-06-19 | MAP | 02 | N | 330013895 | MAP |
| 330003749 | 330001891 | 1.73 | 51 | Neo-adjuvant (N) | 2014-05-14 | 2014-05-20 | Dox + HD Mtx (post PAM) | Y | N | 330013895 | DOXORUBICIN + HD MTX |
| 330003750 | 330001892 | 1.7 | 65.4 | Neo-adjuvant (N) | null | 2013-03-26 | CAP | N | N | 330013907 | CAP |
| 330003751 | 330001893 | 0 | 51.4 | Neo-adjuvant (N) | 2016-12-10 | 2016-12-11 | Carbo F | 02 | N | 330013921 | CARBO + FLUOROURACIL |
| 330003752 | 330001893 | 1.66 | 65.3 | Palliative (P) | 2014-12-30 | 2015-01-04 | CYCLOPHOSPHAMIDE + RITUXIMAB + Dexamethasone | N | N | 330013921 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003753 | 330001893 | 1.57 | 60 | Palliative (P) | 2017-08-08 | 2017-08-08 | CISPLATIN + ETOPOSIDE | 02 | N | 330013921 | CISPLATIN + ETOPOSIDE |
| 330003754 | 330001893 | 1.7 | 113.6 | Palliative (P) | 2014-08-17 | 2014-08-31 | Dox + HD Mtx (post PAM) | N | N | 330013921 | DOXORUBICIN + HD MTX |
| 330003755 | 330001893 | 1.64 | 59.05 | Curative (C) | 2016-11-01 | 2016-11-09 | DA | null | N | 330013921 | DA |
| 330003756 | 330001893 | 1.76 | 59 | Neo-adjuvant (N) | 2017-08-27 | 2017-08-29 | EW EuroEwing 2012 Arm A VIDE | 02 | N | 330013921 | EURO-EWING |
| 330003757 | 330001894 | 1.55 | 75.6 | Disease modification (D) | 2017-08-04 | 2017-08-04 | CVP R | 02 | N | 330013957 | CVP R |
| 330003758 | 330001895 | 1.88 | 87.6 | Curative (C) | 2014-02-04 | 2014-02-09 | EURAMOS TRIAL | null | N | 330013959 | EURAMOS TRIAL |
| 330003759 | 330007025 | null | 153.2 | Neo-adjuvant (N) | 2017-03-25 | 2017-03-26 | Carbo F | N | null | 330013969 | CARBO + FLUOROURACIL |
| 330003760 | 330001896 | 1.43 | 44 | Palliative (P) | null | 2014-03-16 | CISPLATIN + GEMCITABINE | null | null | 330013970 | CISPLATIN + GEMCITABINE |
| 330003761 | 330001896 | 1.65 | 47 | Palliative (P) | 2014-06-25 | 2014-07-04 | GemCarbo Days 1+8 | N | N | 330013970 | GEMCARBO |
| 330003762 | 330001897 | null | 54.9 | Palliative (P) | 2017-07-20 | 2017-07-28 | Carboplatin+Fluorouracil 4 or 5 day | 02 | N | 330013975 | CARBO + FLUOROURACIL |
| 330003763 | 330001897 | 1.84 | 87 | Adjuvant (A) | 2013-06-18 | 2013-07-17 | Cetuximab + Radiotherapy Load | N | Y | 330013975 | CETUXIMAB + RT |
| 330003768 | 330001899 | 1.6 | 62 | Palliative (P) | 2013-12-10 | 2013-12-10 | GemCarbo Days 1+8 | N | N | 330014016 | GEMCARBO |
| 330003769 | 330001899 | 1.86 | 81 | Curative (C) | 2014-01-29 | 2014-02-16 | Cetuximab + Radiotherapy Load | null | null | 330014016 | CETUXIMAB + RT |
| 330003772 | 330009801 | 1.58 | null | Curative (C) | null | 2015-05-28 | EW EuroEwing 2012 Arm A VIDE | null | null | 330014063 | EURO-EWING |
| 330003773 | 330001901 | 1.66 | 67.3 | Palliative (P) | 2017-08-20 | 2017-10-15 | Cisplatin + Etoposide po&iv 3 day | N | N | 330014064 | CISPLATIN + ETOPOSIDE |
| 330003774 | 330001901 | 1.8 | 67.5 | Curative (C) | 2015-08-15 | 2015-09-05 | Cetuximab + Radiotherapy Maint | 02 | N | 330014064 | CETUXIMAB + RT |
| 330003775 | 330001901 | 1.79 | 73 | Curative (C) | null | 2013-12-30 | Dox + HD Mtx (post PAM) | N | N | 330014064 | DOXORUBICIN + HD MTX |
| 330003776 | 330011343 | 1.72 | 59.8 | null | 2016-09-13 | 2016-09-14 | CETUXIMAB + RT | 02 | N | 330014088 | CETUXIMAB + RT |
| 330003777 | 330001902 | 1.72 | 101.85 | Curative (C) | 2015-05-26 | 2015-06-02 | PAM x 2 pre-surgery (cycles 1&2) | 2 | N | 330014091 | MAP |
| 330003778 | 330001902 | null | 59.5 | Neo-adjuvant (N) | 2013-11-27 | 2013-12-04 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 330014091 | CARBO + FLUOROURACIL |
| 330003779 | 330001902 | 1.7 | 57.4 | Palliative (P) | 2016-02-21 | 2016-02-22 | EW EuroEwing 99 : VIDE | N | N | 330014091 | EURO-EWING |
| 330003780 | 330001902 | 1.79 | 47.1 | Curative (C) | 2015-11-12 | 2015-11-23 | EW EuroEwing 99 : VIDE | 2 | N | 330014091 | EURO-EWING |
| 330003784 | 330001903 | 0 | 104 | Curative (C) | 2014-08-05 | 2014-08-15 | CETUXIMAB + RT | Y | N | 330014129 | CETUXIMAB + RT |
| 330003785 | 330001904 | 1.7 | 63 | Curative (C) | 2013-02-28 | 2013-03-16 | Cetuximab + Radiotherapy Load | N | Y | 330014135 | CETUXIMAB + RT |
| 330003787 | 330001906 | 1.78 | 76 | Palliative (P) | 2015-01-22 | 2015-02-05 | CAP | 02 | N | 330014144 | CAP |
| 330003793 | 330012192 | 1.75 | 92 | Palliative (P) | null | 2015-06-15 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330014163 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003794 | 330001908 | 1.66 | 80.5 | Neo-adjuvant (N) | 2014-01-20 | 2014-02-10 | OST Euramos 1 Closed Trial - AP | N | N | 330014166 | MAP |
| 330003795 | 330001909 | 1.77 | 93.7 | Palliative (P) | 2014-07-16 | 2014-07-18 | GemCarbo Days 1+8 | 02 | N | 330014171 | GEMCARBO |
| 330003798 | 330001911 | 0 | 62.4 | Palliative (P) | null | 2014-09-15 | Cetuximab 7 day (Cycle 1) | null | Y | 330014182 | CETUXIMAB |
| 330003803 | 330001913 | 1.72 | null | Curative (C) | 2017-10-17 | 2017-11-07 | Cisplatin + Etoposide po&iv 3 day | 02 | Y | 330014222 | CISPLATIN + ETOPOSIDE |